These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23639146)

  • 1. Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD.
    Hammerness P; Fried R; Petty C; Meller B; Biederman J
    Child Neuropsychol; 2014; 20(3):319-27. PubMed ID: 23639146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains.
    Rhodes SM; Coghill DR; Matthews K
    J Child Psychol Psychiatry; 2006 Nov; 47(11):1184-94. PubMed ID: 17076758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
    Wu CS; Shang CY; Lin HY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
    [No Abstract]   [Full Text] [Related]  

  • 11. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of methylphenidate on cognitive functions in boys with attention deficit hyperactivity disorder: Does baseline performance matter?
    Idema IME; Payne JM; Coghill D
    J Consult Clin Psychol; 2021 Jul; 89(7):615-625. PubMed ID: 34383534
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities.
    Rubio B; Hernández S; Verche E; Martín R; González-Pérez P
    Atten Defic Hyperact Disord; 2011 Mar; 3(1):13-20. PubMed ID: 21432614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate in children with ADHD with or without learning disability.
    Williamson D; Murray DW; Damaraju CV; Ascher S; Starr HL
    J Atten Disord; 2014 Feb; 18(2):95-104. PubMed ID: 22628142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interactive effects of test-retest and methylphenidate administration on cognitive performance in youth with ADHD: A double-blind placebo-controlled crossover study.
    Horowitz I; Avirame K; Naim-Feil J; Rubinson M; Moses E; Gothelf D; Levit-Binnun N
    Psychiatry Res; 2020 Sep; 291():113056. PubMed ID: 32554183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.